New York, NY (PRWEB) December 12, 2012 – German drug manufacturer Boehringer has brought in more than a billion dollars from sales of its blood-thinning drug Pradaxa, according to Bloomberg, but celebration is not in order. The drug has been linked to 500 deaths in the United States over a two-year period, Bloomberg said, and now Boehringer faces up to 150 lawsuits related to serious Pradaxa side effects.
The plaintiffs allege, according to Bloomberg, that Boehringer knew about those potentially serious Pradaxa side effects, including patient “bleed-outs.” The FDA approved Pradaxa in 2010 as a blood-clot prevention alternative to the decades-old warfarin.
But by the following year, the FDA had received reports of 542 deaths and 3,781 side-effect incidents tied to the drug, according to Bloomberg. There were reports outside the United States as well. After European regulators said that 256 deaths were linked to Pradaxa, Boehringer admitted that there were 260 deaths associated with the medication. In New Zealand in 2011, there were dozens of reported deaths as well.